{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T07:23:05Z","timestamp":1789716185420,"version":"4.0.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,9,1]],"date-time":"2018-09-01T00:00:00Z","timestamp":1535760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaad.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2018,9]]},"DOI":"10.1016\/j.jaad.2018.04.018","type":"journal-article","created":{"date-parts":[[2018,4,16]],"date-time":"2018-04-16T13:08:11Z","timestamp":1523884091000},"page":"535-544","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":76,"title":["Topical Janus kinase inhibitors: A review of applications in dermatology"],"prefix":"10.1016","volume":"79","author":[{"given":"Anna-Marie","family":"Hosking","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margit","family":"Juhasz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha Atanaskova","family":"Mesinkovska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jaad.2018.04.018_bib1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1038\/nrrheum.2015.167","article-title":"Type I\/II cytokines, JAKs, and new strategies for treating autoimmune diseases","volume":"12","author":"Schwartz","year":"2016","journal-title":"Nat Rev Rheumatol"},{"issue":"5","key":"10.1016\/j.jaad.2018.04.018_bib2","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40265-017-0701-9","article-title":"JAK\u2013STAT signaling as a target for inflammatory and autoimmune diseases: current and future prospects","volume":"77","author":"Banerjee","year":"2017","journal-title":"Drugs"},{"key":"10.1016\/j.jaad.2018.04.018_bib3","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.phrs.2016.07.038","article-title":"Janus kinase (JAK) inhibitors in the treatment of inflammatory and neoplastic diseases","volume":"111","author":"Roskoski","year":"2016","journal-title":"Pharmacol Res"},{"key":"10.1016\/j.jaad.2018.04.018_bib4","author":"Kavanaugh"},{"issue":"9","key":"10.1016\/j.jaad.2018.04.018_bib5","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.3324\/haematol.2016.143677","article-title":"Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial","volume":"101","author":"Al-Ali","year":"2016","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.jaad.2018.04.018_bib6","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1111\/bjd.12517","article-title":"Effect of tofacitinib, a Janus kinase inhibitor, on haematological parameters during 12 weeks of psoriasis treatment","volume":"169","author":"Strober","year":"2013","journal-title":"Br J Dermatol"},{"issue":"9","key":"10.1016\/j.jaad.2018.04.018_bib7","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1038\/jid.2009.25","article-title":"Double-blind, placebo-controlled, dose-escalation study to evaluate the pharmacologic effect of CP-690,550 in patients with psoriasis","volume":"129","author":"Boy","year":"2009","journal-title":"J Invest Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2018.04.018_bib8","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1111\/j.1365-2133.2012.11168.x","article-title":"Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled dose-ranging study","volume":"167","author":"Papp","year":"2012","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2018.04.018_bib9","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/bjd.12266","article-title":"A randomized phase 2a efficacy and safety trial of the topical Janus kinase inhibitor tofacitinib in the treatment of chronic plaque psoriasis","volume":"169","author":"Ports","year":"2013","journal-title":"Br J Dermatol"},{"issue":"8","key":"10.1016\/j.jaad.2018.04.018_bib10","first-page":"777","article-title":"Randomized pilot clinical trial of tofacitinib solution for plaque psoriasis: challenges of the intra-subject study design","volume":"14","author":"Ports","year":"2015","journal-title":"J Drugs Dermatol"},{"key":"10.1016\/j.jaad.2018.04.018_bib11","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12895-016-0051-4","article-title":"Treatment of plaque psoriasis with an ointment formulation of the Janus kinase inhibitor, tofacitinib: a phase 2b randomized clinical trial","volume":"16","author":"Papp","year":"2016","journal-title":"BMC Dermatol"},{"key":"10.1016\/j.jaad.2018.04.018_bib12","unstructured":"Callis DK, Luchi M, Fidelus-Gort R. Novel mechanism for topical treatment of plaque psoriasis \u2013 results of a randomized, double blind, concentration ranging, vehicle controlled 12 week study with JAK 1\/2 inhibitor INCB018424 cream. The 70th SID meeting; Atlanta GA, USA. 2010. p. 261. J\u00a0Invest Dermatol Abstract."},{"issue":"4","key":"10.1016\/j.jaad.2018.04.018_bib13","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1016\/j.jaad.2011.12.018","article-title":"Preliminary clinical activity of a topical JAK1\/2 inhibitor in the treatment of psoriasis","volume":"67","author":"Punwani","year":"2012","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2018.04.018_bib14","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/bjd.13994","article-title":"Downmodulation of key inflammatory cell markers with a topical Janus kinase 1\/2 inhibitor","volume":"173","author":"Punwani","year":"2015","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2018.04.018_bib15","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1111\/bjd.14871","article-title":"Topical tofacitinib for atopic dermatitis: a phase IIa randomized trial","volume":"175","author":"Bissonnette","year":"2016","journal-title":"Br J Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2018.04.018_bib16","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jamadermatol.2015.4445","article-title":"Topical ruxolitinib for the treatment of alopecia universalis","volume":"152","author":"Craiglow","year":"2016","journal-title":"JAMA Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2018.04.018_bib17","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1177\/1203475417716363","article-title":"A case of topical ruxolitinib treatment failure in alopecia areata","volume":"21","author":"Deeb","year":"2017","journal-title":"J Cutan Med Surg"},{"issue":"1","key":"10.1016\/j.jaad.2018.04.018_bib18","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jaad.2017.03.024","article-title":"Topical Janus kinase inhibitors for the treatment of pediatric\u00a0alopecia areata","volume":"77","author":"Bayart","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2018.04.018_bib21","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/j.jaad.2017.02.049","article-title":"Treatment of vitiligo with the topical Janus kinase inhibitor ruxolitinib","volume":"76","author":"Rothstein","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2018.04.018_bib22","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: the promise of a new drug class","volume":"76","author":"Damsky","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"10.1016\/j.jaad.2018.04.018_bib23","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.jaad.2016.12.004","article-title":"Janus kinase inhibitors in dermatology: a systematic review","volume":"76","author":"Shreberk-Hassidim","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.jaad.2018.04.018_bib24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164080","article-title":"JAK3 as an emerging target for topical treatment of inflammatory skin diseases","volume":"11","author":"Alves de Medeiros","year":"2016","journal-title":"PLoS ONE"},{"issue":"9","key":"10.1016\/j.jaad.2018.04.018_bib25","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1038\/jid.2011.140","article-title":"Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation","volume":"131","author":"Fridman","year":"2011","journal-title":"J Invest Dermatol"},{"issue":"12","key":"10.1016\/j.jaad.2018.04.018_bib26","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1038\/jid.2011.222","article-title":"IL-17A upregulates keratin 17 expression in keratinocytes through STAT1- and STAT3-dependent mechanisms","volume":"131","author":"Shi","year":"2011","journal-title":"J Invest Dermatol"},{"issue":"9993","key":"10.1016\/j.jaad.2018.04.018_bib27","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/S0140-6736(14)62113-9","article-title":"Tofacitinib versus etanercept or placebo in moderate-to-severe chronic plaque psoriasis: a phase 3 randomised non-inferiority trial","volume":"386","author":"Bachelez","year":"2015","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jaad.2018.04.018_bib28","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1111\/bjd.14018","article-title":"Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials","volume":"173","author":"Papp","year":"2015","journal-title":"Br J Dermatol"},{"issue":"3","key":"10.1016\/j.jaad.2018.04.018_bib30","first-page":"e24137","article-title":"The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis","volume":"2","author":"Bao","year":"2013","journal-title":"JAKSTAT"},{"issue":"3","key":"10.1016\/j.jaad.2018.04.018_bib31","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.jaci.2015.03.051","article-title":"The Janus kinase\u00a0inhibitor JTE-052 improves skin barrier function through suppressing signal transducer and activator of transcription 3 signaling","volume":"136","author":"Amano","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.jaad.2018.04.018_bib32","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1124\/jpet.115.223784","article-title":"Topically administered janus-kinase inhibitors tofacitinib and oclacitinib display impressive antipruritic and anti-inflammatory responses in a model of allergic dermatitis","volume":"354","author":"Fukuyama","year":"2015","journal-title":"J Pharmacol Exp Ther"},{"issue":"3","key":"10.1016\/j.jaad.2018.04.018_bib33","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jaad.2015.06.045","article-title":"Treatment of recalcitrant atopic dermatitis with the oral Janus kinase inhibitor tofacitinib citrate","volume":"73","author":"Levy","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"10.1016\/j.jaad.2018.04.018_bib34","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/vde.12088","article-title":"A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel\u00ae) in client-owned dogs with atopic dermatitis","volume":"24","author":"Cosgrove","year":"2013","journal-title":"Vet Dermatol"},{"issue":"5","key":"10.1016\/j.jaad.2018.04.018_bib35","doi-asserted-by":"crossref","first-page":"479-e114","DOI":"10.1111\/vde.12047","article-title":"Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis","volume":"24","author":"Cosgrove","year":"2013","journal-title":"Vet Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2018.04.018_bib37","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.cell.2013.08.057","article-title":"The epithelial cell-derived atopic dermatitis cytokine TSLP activates neurons to induce itch","volume":"155","author":"Wilson","year":"2013","journal-title":"Cell"},{"issue":"2","key":"10.1016\/j.jaad.2018.04.018_bib38","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.jaci.2013.10.048","article-title":"A Sensory neuron-expressed interleukin-31 receptor mediates T helper cell-dependent itch: involvement of TRPV1 and TRPA1","volume":"133","author":"Cevikbas","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"12","key":"10.1016\/j.jaad.2018.04.018_bib39","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1038\/jid.2014.260","article-title":"Killing two birds with one stone: oral tofacitinib reverses alopecia universalis in a patient with plaque psoriasis","volume":"134","author":"Craiglow","year":"2014","journal-title":"J Invest Dermatol"},{"issue":"1","key":"10.1016\/j.jaad.2018.04.018_bib40","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ajh.23871","article-title":"Ruxolitinib-induced reversal of alopecia universalis in a patient with essential thrombocythemia: ruxolitinib-induced reversal of alopecia universalis in a patient","volume":"90","author":"Pieri","year":"2015","journal-title":"Am J Hematol"},{"issue":"4","key":"10.1016\/j.jaad.2018.04.018_bib41","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ebiom.2015.02.015","article-title":"Reversal of alopecia areata following treatment with the JAK1\/2 inhibitor baricitinib","volume":"2","author":"Jabbari","year":"2015","journal-title":"EBioMedicine"},{"issue":"15","key":"10.1016\/j.jaad.2018.04.018_bib42","article-title":"Safety and efficacy of the JAK inhibitor tofacitinib citrate in patients with alopecia areata","volume":"1","author":"Crispin","year":"2016","journal-title":"JCI Insight"},{"issue":"15","key":"10.1016\/j.jaad.2018.04.018_bib43","doi-asserted-by":"crossref","first-page":"e89790","DOI":"10.1172\/jci.insight.89790","article-title":"Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata","volume":"1","author":"Mackay-Wiggan","year":"2016","journal-title":"JCI Insight"},{"key":"10.1016\/j.jaad.2018.04.018_bib44","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1346-8138.2010.01139.x","article-title":"Vitiligo: a review of the published work","volume":"38","author":"Yaghoobi","year":"2011","journal-title":"J\u00a0Dermatol"},{"issue":"223","key":"10.1016\/j.jaad.2018.04.018_bib45","doi-asserted-by":"crossref","first-page":"223ra23","DOI":"10.1126\/scitranslmed.3007811","article-title":"CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo","volume":"6","author":"Rashighi","year":"2014","journal-title":"Sci Transl Med"},{"issue":"10","key":"10.1016\/j.jaad.2018.04.018_bib46","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamadermatol.2015.1520","article-title":"Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-directed therapy","volume":"151","author":"Craiglow","year":"2015","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.jaad.2018.04.018_bib48","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1021\/acs.jmedchem.6b01634","article-title":"Design and synthesis of a pan-Janus kinase inhibitor clinical candidate (PF-06263276) suitable for inhaled and topical delivery for the treatment of inflammatory diseases of the lungs and skin","volume":"60","author":"Jones","year":"2017","journal-title":"J Med Chem"},{"issue":"1","key":"10.1016\/j.jaad.2018.04.018_bib49","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/exd.13370","article-title":"A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: comparison with conventional therapeutic agents","volume":"27","author":"Tanimoto","year":"2018","journal-title":"Exp Dermatol"}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218305620?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962218305620?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,30]],"date-time":"2025-09-30T22:46:06Z","timestamp":1759272366000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962218305620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":44,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,9]]}},"alternative-id":["S0190962218305620"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2018.04.018","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Topical Janus kinase inhibitors: A review of applications in dermatology","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2018.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 by the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}